1	Appraising the causal association between gut microbiota and
2	immune-related adverse events: perspectives from a bi-directional
3	Mendelian randomization study
4	
5	Baike Liu ^{1,2,5} , Zheran Liu ^{3,5} , Tianxiang Jiang ^{1,2,5} , Xiangshuai Gu ⁴ , Xiaonan Yin ^{1,2} ,
6	Zhaolun Cai ^{1,2} , Xiaoqiao Zou ^{1,2} , Lei Dai ^{4*} , Bo Zhang ^{1,2*}
7	
8 9	¹ Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, the People's Republic of China.
10 11	² Gastric Cancer Center, West China Hospital, Sichuan University. Chengdu, Sichuan, 610041, the People's Republic of China.
12 13 14	³ Department of Biotherapy and National Clinical Research Center for Geriatrics, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, the People's Republic of China.
15 16 17	⁴ State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan, 610041, the People's Republic of China.
18	⁵ These authors contributed equally: Baike Liu, Tianxiang Jiang, Zheran Liu.
19	*e-mail: <u>zhangbo_scu@scu.edu.cn</u> , daileisklb2012@163.com
20	
21	
22	Running title: Causal associations between gut microbiota and irAEs
23 24	
25	
26	
27	
28	
29	
30	
31 32	
04	

33 Abstract:

Background: Emerging evidence suggested that the gut microbiota associated with the development of immune-related adverse effects (irAEs) among cancer patients receiving immune checkpoint inhibitors (ICIs), but their roles remain largely unknown, and the causal associations are yet to be clarified.

Methods: Bi-directional two-sample Mendelian randomization (MR) approach was employed to examine the potential causal relationship between the gut microbiome and irAEs (high-grade irAEs and all-grade irAEs). Instrumental variables (IVs) for

41 gut microbiota were retrieved from the MiBioGen consortium (18,340 participants).

42 GWAS summary data for instrument-outcome associations were gathered from an

43 ICIs-treated cohort with 1,751 cancer patients. Inverse variance weighted (IVW), MR

44 PRESSO, maximum likelihood (ML), weighted median, weighted mode, and 45 cML-MA-BIC were used in the MR analysis. Reverse MR analysis was performed on

the identified bacteria that were causally associated with irAEs.

Results: Fourteen gut bacterial taxa identified by IVW and MR PRESSO were 47 48 causally associated with irAEs, among which Lachnospiraceae was shown to increase 49 the risk of both high-grade and all-grade irAEs. Akkermansia, Verrucomicrobiaceae, 50 and Anaerostipes were found to exert protective roles in high-grade irAEs. 51 Nevertheless, Ruminiclostridium6, Coprococcus3, Collinsella, and Eubacterium 52 (*fissicatena group*) predispose to the development of high-grade irAEs. For all-grade irAEs, RuminococcaceaeUCG004, and DefluviitaleaceaeUCG011 were shown to 53 54 have protective effects. While on the contrary, Porphyromonadaceae, Roseburia, Eubacterium (brachy group), and Peptococcus were associated with an elevated risk 55 56 of all-grade irAEs.

57 **Conclusion:** Our MR analysis found that *Lachnospiraceae* and *Akkermansia* et al. 58 were causally associated with the development of irAEs, which warrants further 59 investigation.

- 60
- 61

62 Key words: Gut microbiota, Immune-related adverse effects, irAEs, Lachnospiraceae,

- 63 Akkermansia, Mendelian randomization study
- 64
- 65
- 66
- 67
- 68
- 69

70 **1. Introduction**

Applications of immune checkpoint inhibitors (ICIs), especially those targeting 71 72 CTLA-4 and PD-1/PD-L1, have revolutionized the treatment of various aggressive 73 cancers (1). By blocking inhibitory signaling pathways and reinvigorating the natural 74anti-tumor immune response, these inhibitors have significantly prolonged the lives of 75 numerous cancer patients (2-5). However, due to the inhibition of the systemic brake 76 of immune activation, ICIs can cause off-target effects resulting in immune-mediated 77 impairment of organs and non-malignant tissues. This newly emerging registry of 78 iatrogenic effects, known as immune-related adverse effects (irAEs), usually resemble 79 autoimmune disorders, such as colitis, dermatitis, and thyroiditis (6). Although the majority of irAEs manifest in a mild manner, still, up to 55% of patients develop 80 serious irAEs in combined therapy (anti-CTLA-4 and anti-PD-1) (7). Notably, serious 81 82 irAEs pose significant risks to patients' well-being and may result in morbidity and 83 mortality, not only due to the adverse event itself but also due to the need to suspend 84 or terminate ICIs therapy and the potential impairment of the ICIs-induced immune response while using immunosuppressants (e.g. corticosteroids) (8-10). Therefore, 85 86 effective management of irAEs is critical to optimize the safety and efficacy of ICIs 87 therapy.

88 The precise mechanisms underlying irAEs are not fully understood, but 89 emerging evidence indicates that the gut microbiota, a complex and dynamic system 90 of microorganisms colonizing the intestinal tract, may play a crucial role in the 91 regulation of irAEs. Simpson et al. found a reduced alpha-diversity of intestinal 92 microbiota in patients who developed severe irAEs (11). Furthermore, antibiotics 93 commonly prescribed prophylactically to hospitalized patients have been shown to 94 increase the risk of ICIs therapy-related irAEs that are not limited to the 95 gastrointestinal tract (12–14). The gut microbiota is closely interacted with the host immune system and has been implicated in the regulation of various autoimmune and 96 97 inflammatory disorders (15,16). However, consensus on the core microbial drivers or 98 protective microbes of irAEs is still lacking, due to inconsistent findings reported in 99 previous studies (11,17–19). The discrepancies among previous studies may be 100 attributed to limited sample sizes and susceptibility to confounding factors such as age, diet, and medication usage in observational designs (11,20). 101

Mendelian randomization (MR), initially described by Katan in 1986 (21), is a novel method for inferring causal associations between modifiable risk factors and health outcomes using genetic variations as instrumental variables (IVs) (22). MR effectively addresses the limitations of confounding and measurement errors that often exist in observational studies, as the direction of causation is from the genetic polymorphism to the trait of interest, not vice versa (23). Therefore, we aim to utilize

MR, an increasingly popular method in drug discovery and epidemiology (24,25), to investigate the potential association between the gut microbiota and irAEs, providing further evidence for the management of irAEs through manipulating the human gut microbiota.

112

113 **2. Methods**

114 Study design and data source

115 An overview of the study design was illustrated in **Figure 1**. In general, we 116 performed a bi-directional two-sample Mendelian randomization, a genetic instrumental variable analysis that utilizes single nucleotide polymorphisms (SNPs) 117 118 from summary-level data as genetic instruments for the risk factor under investigation. 119 To ensure the validity of the MR results, three assumptions needed to be satisfied, as 120 illustrated in Figure S1 (22): (1) the genetic variants should demonstrate a strong 121 association with the exposure (relevance assumption); (2) the genetic variants should 122 not be associated with any confounders that could affect the relationship between the 123 exposure and outcome (independence assumption); and (3) the variants should not have an independent effect on the outcome aside from their impact through the 124 125exposure (exclusion restriction assumption). This study is based on publicly available 126 GWAS summary statistics and ethical approvals were acquired in the original study.

127

128 Gut microbiota: Genetic variations associated with the composition of gut 129 microbiota were derived from the most comprehensive genome-wide meta-analysis 130 conducted to date by the MiBioGen consortium (26). This study included a total of 131 18,340 individuals from 24 cohorts worldwide, mainly of European descent (n =132 13,266). Fecal DNA was extracted, and targeted sequencing of variable regions in the 133 bacterial 16S rRNA gene (V4, V3-V4, and V1-V2 regions) was performed to profile 134 the gut bacterial composition. To account for sequencing depth differences across cohorts, all cohorts were rarefied to 10,000 reads per sample. Taxonomic 135 136 classification was performed using direct taxonomic binning method (26). Following 137 quality control, imputation, and post-imputation filtering procedures, gut bacterial 138 taxa observed in over 10% of samples were included in the microbiota quantitative 139 trait loci (mbQTL) mapping (26). This allowed us to identify host genetic variants 140 associated with the relative abundance of bacterial taxa. Further details on microbial 141 data processing can be found in the original study. Genus-level and family-level taxa 142 were included in our analysis, resulting in a total of 131 genus-level and 35 143 family-level taxa.

144 145

irAEs: Summary-level data of irAEs was obtained from a recent GWAS

conducted in the Dana-Farber Cancer Institute (DFCI) cohort (27). The study included 146 147 1,751 cancer patients of European ancestry who underwent ICIs treatments between 2013 and 2020. The majority of patients (approximately 90%) received PD-1/PD-L1 148 149 inhibitors, while the remaining 10% received combined immunotherapy (CTLA4 and 150 PD-1/PD-L1 inhibitors). Among the 1,751 cancer patients, 259 cases that experienced 151 high-grade irAEs (grade 3 to 5 events) were manually curated according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events 152153 v.5 guidelines. Additionally, algorithm-based autoimmune-like electronic health 154 records were used to identify 339 patients who experienced any grade irAEs (referred to as all-grade irAEs). Most of these cases were grade 2 or higher events (27). The 155 156 tumor tissue of these patients was sequenced using the targeted OncoPanel 157 sequencing platform. After quality control steps, germline SNPs were imputed by 158 utilizing ultra-low-coverage off-target reads. Then, the GWAS was conducted in the 159 DFCI cohort to investigate the association of all variants with the time from the start 160 of ICIs treatment to the occurrence of the two phenotypes of irAEs. For more detailed 161 information, please refer to the original publication (27).

162

163 Selection of instrumental variables

164 Several steps were followed in the selection of IVs. Firstly, for the gut microbiome, we selected SNPs associated with bacterial taxa with a p-value less than 165 1×10^{-5} for further analysis (28,29). Secondly, potential SNPs were clumped for 166 167 independence in the TwoSampleMR package in R software. We used the European 1000 Genomes Project Phase 3 reference panel and set the linkage-disequilibrium 168 threshold (r^2) at 0.001 within a 10 Mb window size. Thirdly, we extracted SNPs from 169 the outcome statistics and performed a harmonization procedure. SNPs that were not 170 available in the outcome GWAS data were replaced with proxy SNPs ($r^2 > 0.8$), and 171 palindromic SNPs were removed for further MR analysis. Furthermore, F statistics of 172173 selected IVs, which indicate instrument strength, was calculated as $[Beta/SE]^2$. Typically, F statistics > 10 suggest enough IVs strength to avoid weak instrument bias 174 175 (30). Finally, All SNPs with positive results were re-examined using PhenoScanner 176 package (version 1.0) in R software to investigate the presence of potential 177 confounders. Bacterial taxa with less than 3 valid SNPs and unknown origin were 178 excluded from the analysis to mitigate potential bias. Consequently, we included a 179 total of 104 genus-level and 28 family-level bacterial taxa (n = 132) for further MR 180 analysis.

182 Statistical analysis

183 In this study, we employed several MR analysis methods to explore the potential 184 causal relationship between gut microbiota and irAEs. The methods used included 185 IVW, MR PRESSO, ML, weighted median, weighted mode, and a constrained 186 maximum likelihood and model averaging based method (cML-MA-BIC). IVW and 187 MR PRESSO were used in the primary analysis. In general, IVW provides maximum 188 statistical power when all instruments are valid (31), while MR PRESSO identifies and removes genetic variants that deviate significantly from the variant-specific 189 190 causal estimates of other variants, thereby increasing statistical power and addressing 191 potential outliers (32). The ML method is similar to the IVW approach which assumes 192 the absence of both heterogeneity and horizontal pleiotropy. If these assumptions hold 193 true, the ML method yields unbiased results with smaller standard errors compared to 194 the IVW approach (33). Considering the potential existence of IV pleiotropy, we also 195 performed pleiotropy-robust methods including weighted median, weighted mode, 196 and cML-MA-BIC in the sensitivity analysis. These methods relax the instrumental 197 variable assumptions. Weighted median were introduced when the exclusion 198 restriction assumption was violated (uncorrelated pleiotropy), which typically assume 199 fewer than 50% of genetic variants are invalid (34). The weighted-mode method 200 clusters genetic variants based on their similarity in causal effect and estimates the 201 overall causal effect based on the cluster with the most number of IVs (35). The 202 cML-MA-BIC method is a novel approach developed for MR analysis, specifically 203 addressing the issue of invalid IVs exhibiting both uncorrelated and correlated 204 pleiotropy (violation of the independence assumption) (36). By being robust to such 205 violations, cML-MA-BIC improves the accuracy of MR analysis, reduces Type I error, 206 and increases statistical power (36).

207 Next, heterogeneity and directional pleiotropy were assessed using Cochran's Q 208 statistics and MR Egger intercept. Leave-one-out (LOO) analysis was conducted to 209 identify possible reliance on a specific variant, which involved excluding one SNP at 210 a time for all valid SNPs in the IVW analysis. Additionally, reverse MR analysis 211 between irAEs and the identified significant gut bacterial taxa was performed. We considered a Bonferroni-corrected p-value of 3.89 \times 10⁻⁴ (0.05/132) as the 212 213 significance threshold for gut microbiota. Two-tailed p-values < 0.05 was considered 214 suggestive of significance. All analyses were conducted using R packages 215"TwoSampleMR" (version 0.5.6), "MRPRESSO" (version 1.0), and "MRcML" 216 (version 0.0.0.9) in R software (version 4.2.2).

217

218 **3. Results**

219 **3.1 Genetic instruments and primary MR analysis**

220 A total of 870 single nucleotide polymorphisms (SNPs) were selected as 221 instrumental variables (IVs) for the 132 gut bacterial taxa (Table S1). The F statistics 222 for each SNP ranged from 16.91 to 36.57, with a median value of 21.66. Using the 223 IVW and MR-PRESSO methods, eight gut bacterial taxa associated with high-grade 224 irAEs were identified with p-values < 0.05. These taxa include *Lachnospiraceae*, 225Verrucomicrobiaceae, Ruminiclostridium6, Coprococcus3, Anaerostipes, 226 Akkermansia, Collinsella, and Eubacterium (fissicatena group). For all-grade irAEs, 227 seven gut bacterial taxa, including Lachnospiraceae, Porphyromonadaceae, 228 Roseburia, RuminococcaceaeUCG004, DefluviitaleaceaeUCG011, Eubacterium 229 (brachy group), and Peptococcus, were identified. Given previous studies suggest that 230 pre-existing autoimmune conditions such as inflammatory bowel disease, psoriasis, 231and rheumatoid arthritis may predispose individuals to irAEs susceptibility (37,38). 232 We further examined the SNPs associated with the significant bacterial taxa using 233 PhenoScanner. Only one SNP (rs11597285) for the *Collinsella* genus was found to be 234 associated with allergic disease (e.g. allergic rhinitis and eczema) (refer to Table S9). 235However, the results of *Collinsella* remained uninfluenced after removing rs11597285 236 in the LOO analysis (described below). The complete results of the primary MR analysis can be found in Table S2 and Table S3. 237

238

3.2 Main MR results and sensitivity analysis for high-grade irAEs

240 As shown in Figure 2, the IVW estimate suggested the abundance of Lachnospiraceae family was associated with a shortened time to high-grade irAEs 241 (Beta = -1.22, 95% CI: -1.99 to -0.44, $p = 2.17 \times 10^{-3}$), indicating *Lachnospiraceae* 242 serves as a risk factor for the development of high-grade irAEs. The deleterious effect 243 remained significant in pleiotropy-robust cML-MA-BIC estimation (Beta = -1.24, 95% 244 CI: -2.45 to -0.02, $p = 4.62 \times 10^{-2}$). Surprisingly, *Ruminiclostridium* genus was 245 significantly associated with an increased risk of high-grade irAEs in all MR 246 approaches, including IVW (Beta = -2.11, 95% CI: -2.98 to -1.23, $p = 2.47 \times 10^{-6}$). 247 cML-MA-BIC (Beta = -2.17, 95% CI: -3.49 to -0.86, $p = 1.19 \times 10^{-3}$), Weighted 248 median (Beta = -2.43, 95% CI: -4.05 to -0.81, $p = 3.29 \times 10^{-3}$), and other methods. In 249 addition, the IVW estimate indicated a protective effect of the Akkermansia genus on 250 high-grade irAEs (Beta = 1.27, 95% CI: 0.28 to 2.25, p = 0.01), and this finding was 251252 confirmed by the IVW estimate of its paternal taxon Verrucomicrobiaceae (Beta = 2531.27, 95% CI: 0.29 to 2.25, p = 0.01). The IVW estimate of Anaerostipes genus also indicated a suggestive protective effect against high-grade irAEs (Beta = 2.1, 95% CI: 2540.85 to 3.35, $p = 1.02 \times 10^{-3}$), as well as cML-MA-BIC (Beta = 2.17, 95% CI: 0.57 to 255

256 $3.77, p = 7.88 \times 10^{-3}$). Moreover, significant effects of the *Coprococcus3* (Beta = 257 -2.04, 95% CI: -2.7 to -1.39, p = 8.93×10^{-10}), *Collinsella* (Beta = -1.12, 95% CI: -1.7 258 to -0.53, p = 1.7×10^{-4}), and *Eubacterium (fissicatena group)* genus (Beta = -0.73, 95% 259 CI: -1.01 to -0.46, p = 1.93×10^{-7}) were all revealed by IVW estimate, indicating an 260 increased risk of high-grade irAEs. Scatter plots reflecting the effect size of IVs on 261 both bacterial taxa and high-grade irAEs are shown in **Figure 4**.

262 In the subsequent analysis of heterogeneity and horizontal pleiotropy, Cochran's Q statistics revealed no significant heterogeneity (p-value > 0.05) among the IVs for 263 264 the gut bacterial taxa in high-grade irAEs analysis (see **Table 1**). No significant evidence for directional horizontal pleiotropy was found in the MR-Egger regression 265266 intercept analysis and MR PRESSO global test (Table 1 and Table S4). Additionally, 267 the LOO analysis identified no predominant SNP that influenced the results (Figure 6). We further performed reverse MR analysis and demonstrated no reverse causation 268 269 exists between high-grade irAEs and the abundance of gut bacterial taxa (Table S6).

270

3.3 Main MR results and sensitivity analysis for all-grade irAEs

272 Figure 3 presents the association between bacterial taxa and all-grade irAEs. It is 273 noteworthy that the deleterious impact of the Lachnospiraceae family was also detected in all-grade irAEs, as revealed by IVW (Beta = -2.05, 95% CI: -3.27 to -0.82, 274 $p = 1.06 \times 10^{-3}$), cML-MA-BIC (Beta = -2.21, 95% CI: -3.32 to -1.1, $p = 9.16 \times 10^{-5}$), 275and Weighted median estimates (Beta = -1.72, 95% CI: -3.2 to -0.24, $p = 2.25 \times 10^{-2}$). 276 277 The IVW estimate of Roseburia genus also showed an increased risk of all-grade irAEs (Beta = -2.07, 95% CI: -3.21 to -0.93, $p = 3.76 \times 10^{-4}$). Consistent results were 278 observed in ML (Beta = -2.07, 95% CI: -3.67 to -0.47, $p = 1.14 \times 10^{-2}$) and 279cML-MA-BIC (Beta = -2.08, 95% CI: -3.71 to -0.45, $p = 1.23 \times 10^{-2}$) estimates. On 280 the contrary, *RuminococcaceaeUCG004* (Beta = 1.07, 95% CI: 0.43 to 1.72, p = 1.05 281 \times 10⁻³) and *DefluviitaleaceaeUCG011* (Beta = 0.82, 95% CI: 0.38 to 1.25, p = 2.15 \times 282 283 10^{-4}) were identified to decrease the risk of all-grade irAEs according to the IVW approach. Subsequently, the results for RuminococcaceaeUCG004 were consistent 284 with the cML-MA-BIC (Beta = 1.1, 95% CI: 0.04 to 2.15, $p = 4.12 \times 10^{-2}$) and ML 285 method (Beta = 1.09, 95% CI: 0.04 to 2.14, $p = 4.16 \times 10^{-2}$). Moreover, the IVW 286 estimates suggested that Porphyromonadaceae (Beta = -1.11, 95% CI: -1.83 to -0.39, 287 $p = 2.46 \times 10^{-3}$), Eubacterium (brachy group) (Beta = -0.71, 95% CI: -1.14 to -0.27, p 288 $= 1.38 \times 10^{-3}$), and *Peptococcus* (Beta = -0.71, 95% CI: -1.24 to -0.18, p = 8.82×10^{-3}) 289 may increase the risk of all-grade irAEs. Scatter plots reflecting the effect size of each 290 IV on both bacterial taxa and all-grade irAEs are shown in **Figure 5**. 291

Similarly, Cochran's Q statistics indicated an absence of notable heterogeneity in the IVs of gut bacterial taxa (refer to **Table 1**). In addition, the results from the MR-Egger regression intercept analysis and the MR PRESSO global test

demonstrated no significant evidence of directional horizontal pleiotropy (**Table 1** and **Table S4**). Next, no significant single SNP was identified in the LOO analysis that influenced the results (**Figure 7**). Overall, these results provide evidence for the association between specific gut bacterial taxa and the development of high-grade and all-grade irAEs, and highlight the potential role of the gut microbiota in irAEs.

300

301 **4. Discussion**

302 In this study, we implemented the summary statistics of gut microbiota from the 303 largest GWAS meta-analysis and the summary statistics of irAEs in the MR analysis. Fourteen gut bacterial taxa were identified to be causally associated with high-grade 304 305 and all-grade irAEs. Among those bacterial taxa, Lachnospiraceae showed a strong 306 causal association with an increased risk of both irAEs phenotypes. Additionally, we 307 found robust evidence indicating that Ruminiclostridium6 predisposes ICIs receivers 308 to the development of high-grade irAEs. Coprococcus3, Collinsella, and Eubacterium 309 (*fissicatena group*) were also associated with an increased risk of high-grade irAEs, 310 while Akkermansia, Verrucomicrobiaceae, and Anaerostipes exhibited protective roles 311 in high-grade irAEs. For all-grade irAEs, Porphyromonadaceae, Roseburia, 312 *Eubacterium (brachy group)*, and *Peptococcus* were associated with an elevated risk, 313 while RuminococcaceaeUCG004 and DefluviitaleaceaeUCG011 were associated with 314 a reduced risk.

315 Several observational studies have demonstrated associations between gut 316 microbiota and irAEs (11,17–19,39,40). Lachnospiraceae species (such as 317 *Coprococcus* and *Roseburia*), which are obligately anaerobic, variably spore-forming bacteria, were found to correlate with increased risk of various types of irAEs 318 (17,18,41). In a more recent study, two species of the Lachnospiraceae family were 319 320 specifically enriched in irAEs that occur in endocrine organs (42). Consistent with these findings, we identified the Lachnospiraceae family, and its two genera (i.e., 321 322 Coprococcus3 and Roseburia) associated with an increased risk of irAEs. Importantly, 323 the detrimental influence of the *Lachnospiraceae* family was observed in high-grade 324 irAEs and all-grade irAEs, providing further validity and robustness to our study. 325 Ruminiclostridium6 has been less studied in irAEs, but some studies have observed its 326 accumulation in a mouse model of DSS-induced colitis. While treated with phloretin 327 (a dihydrochalcone flavonoid) or sodium butyrate (one of the short chain fatty acids [SCFAs]), both of which alleviates DSS-induced colitis, the abundance of 328 329 Ruminiclostridium6 was reduced (43,44). In addition, the Ruminiclostridium genus 330 has also been associated with autoimmune-related diseases, such as experimental 331 multiple sclerosis model and Alzheimer's disease (45,46). Based on our strong 332 association of *Ruminiclostridium6* with increased risk of high-grade irAEs, it is

suggested that *Ruminiclostridium6* may play a pivotal role in the development of
 autoimmune conditions and could be a potential target for relieving irAEs symptoms,
 although more evidence is needed.

336 Akkermansia muciniphila, an anaerobic gram-negative species that belongs to 337 Akkermansia genus, and Verrucomicrobiaceae family, has gained much attention in immunotherapy due to their association with a favorable response in ICIs therapy 338 339 (47–49). Akkermansia muciniphila has also been shown to exhibit a protective role in ICIs-associated colitis (50). Mechanically, Wang et al. demonstrated that Akkermansia 340 341 *muciniphila* and its purified membrane protein mitigated colitis by regulating 342 macrophages and CD8+ T cells in the colon tissue (51). Our study further supported 343 the protective role of Akkermansia in high-grade irAEs. Ruminococcaceae, a key 344 family of bacteria producing short-chain fatty acids (SCFAs), has been observed to be enriched in ICIs responders without severe irAEs (11). Previous studies have found 345 346 that Faecalibacterium prausnitzii, a species belonging to the Ruminococcaceae family, 347 was decreased in non-responders and those experiencing severe irAEs (11,17,41). 348 These findings suggest a potential role of *Ruminococcaceae* as protective bacteria, 349 possibly through the facilitation of SCFAs accumulation, in the mitigation of irAEs. 350 Collinsella and Anaerostipes have limited evidence in irAEs, but the Collinsella 351 genus has been reported to increase the production of IL-17A and enhance rheumatoid 352 arthritis severity (52). In contrast, Anaerostipes, which belongs to the Lachnospiraceae family, was conversely associated with the risk of high-grade irAEs 353 354 in our study (11,18). These discrepancies observed in previous clinical studies might 355 be attributed to several factors, including limited sample sizes in previous 356 observational studies, heterogeneity among the samples, and inadequate exploration of the taxonomic classification at the genus level of the gut microbiota. Therefore, a 357 more detailed taxonomy for gut microbiota is crucial in dissecting the underlying 358 359 mechanisms.

360 Gut microbiota plays a pivotal role in modulating human immune homeostasis, 361 and an imbalance in gut microbial composition, known as gut dysbiosis, has been 362 implicated in several autoimmune diseases (15,16,53). Notably, irAEs resemble autoimmune diseases in many aspects (37,54,55). Thus, despite the underlying 363 364 mechanisms by which gut microbiota manipulates the development of irAEs remain 365 poorly understood, we hypothesize that there might be some shared etiology of 366 microbiota in autoimmune diseases and irAEs. These mechanisms include: (1) 367 "Molecular mimicry": Evidence has shown that exposure to homologous amino acid 368 sequences or epitopes of microbiota and aberrant activation of autoreactive B or T 369 cells leads to multiple autoimmune diseases, such as multiple sclerosis (56), 370 Guillain-Barré syndrome (57), Type 1 diabetes (58), Rheumatoid arthritis (59), and 371 primary biliary cholangitis (60), which is referred to as "molecular mimicry" (61). It

372 is believed that the systematic activation of the immune system during ICIs treatment 373 triggers irAEs by bypassing self-tolerance in normal organs. One intriguing fact is 374 that most irAEs occur in barrier organs (e.g., the intestinal tract, skin, and lungs) 375 (54,62). This implies that the activated immune response might target the commensal 376 microbiome as antigenic targets, although this hypothesis has not been fully 377 demonstrated. (2) Decreased accumulation of SCFAs: SCFAs, including acetate, 378 propionate, and butyrate, are a group of organic compounds primarily produced by the 379 gut microbiota during the fermentation of dietary fibers. These metabolites were 380 shown to improve the anti-cancer function of effector T cells, but they also seem to 381 exhibit anti-inflammatory characteristics (63,64). Butyrate, one of the well-studied 382 SCFAs, was shown to inhibit the activation of NF- κ B and its downstream pathway 383 (65), thereby reducing the production of pro-inflammatory cytokines such as IL-8 (66), 384 while increasing the levels of anti-inflammatory factors like IL-10 (67). Moreover, 385 SCFAs serve as a key energy source for colonocytes and maintain intestinal barrier 386 integrity (68). Thus, the reduced abundance of SCFAs-producing bacteria along with 387 its metabolites may participate in the development of irAEs. (3) Other mechanisms: 388 Stimulation of the immune response by microbial-associated molecular patterns (e.g., 389 include lipopolysaccharides (LPS), lipoproteins, flagellin and bacterial DNA) (69) 390 and compromised vitamin B and polyamine metabolism that associated with gut 391 dysbiosis (19) may also contribute to irAEs.

392 Taken together, the gut microbiota and the human immune system maintain a 393 delicate balance under normal physiological conditions. Once the balance has been 394 disturbed (e.g., ICIs treatment), the dysregulated microbiota might lead to the 395 development of undesirable irAEs. The primary management strategy for irAEs (> 396 grade 2) involves the suspension of ICIs and/or utilizing immunosuppressive therapy concern is discontinuing 397 (70).Nevertheless, one that ICIs or using 398 immunosuppressants may compromise treatment efficacy. Ideally, approaches to 399 boost ICIs efficacy while reducing the accompanied irAEs are to be expected in the 400 future. FMT, an approach to modulate gut microbiota, has been shown to increase 401 ICIs efficacy in melanoma patients (71,72), and emerging evidence has demonstrated 402 the mitigation of ICIs-related colitis through FMT in clinical practice (73). 403 Interestingly, while irAEs and ICIs efficacy are often considered two sides of the 404 same coin, certain gut bacteria, such as Akkermansia muciniphila and 405 Faecalibacterium prausnitzii, have been shown to ameliorate irAEs and reinforce 406 ICIs efficacy at the same time (74). This suggests that targeting gut microbiota could 407 be an ideal approach to relieve irAEs symptoms and maintain ICIs efficacy, but 408 further real-world evidence is needed to support this hypothesis.

409 Our study possesses several strengths. Firstly, we applied the MR approach to the 410 causal-association analysis between gut microbiota and irAEs, which effectively

411 mitigates the influence of confounding factors and provides robust causal inference. 412 Secondly, we conducted reverse MR analyses, confirming the absence of reverse 413 causation, thereby enhancing the validity of our study. Thirdly, the genetic variants 414 associated with the gut microbiota were obtained from a comprehensive meta-analysis 415 of GWAS, ensuring the reliability of the instrumental variables used in the MR 416 analysis. Moreover, we incorporated several pleiotropy-robust methods such as MR 417 PRESSO and cML-MA-BIC, further strengthening the robustness of our study. 418 However, there are also certain inherent limitations in our study that should be 419 considered when interpreting the findings. Firstly, our analysis is based on 420 European-derived GWAS summary statistics, which might confine the generalization 421 of the findings to other populations. Secondly, due to the utilization of summary 422 statistics instead of raw data in the analysis, subgroup analyses based on ICIs regimes 423 (e.g. PD-1/PD-L1 group, CTLA-4 group, and combined therapy group) could not be 424 performed. Thirdly, the gut microbiota is shaped by multiple environmental factors, which confines the number of the identified significant gene loci in the GWAS (26). 425 Thus, we relaxed the significant threshold of IVs to 1×10^{-5} (29) and employed 426 427 Bonferroni correction to mitigate potential false positive results.

428

429 **5. Conclusion**

In summary, our findings suggest that *Lachnospiraceae* and *Akkermansia* et al. were causally associated with the development of irAEs. However, whether the FMT or probiotics could be used as interventional approaches to mitigate irAEs while reserving ICIs efficacy, additional randomized clinical trials (RCTs) are warranted. Furthermore, in-depth investigations are needed to elucidate the precise mechanisms through which the gut microbiota influences the development of irAEs.

436

437 **Declarations**

438 Acknowledgment:

439 We acknowledge all the investigators who have made their GWAS data available.

440

441 **Author contributions**

B. L. conceptualized this study. B. L. and T. J., Z. L. were involved in the analyses and manuscript drafting of this study. X. G. and X. Z. were involved in the data curation. B. L., T. J. X. Y., Z. C., and L. D. were involved in the interpretation of the methodology and results. B. L. and Z. L. were involved in the visualization of the results. B. Z. was involved in obtaining funding and critical revision of the manuscript.

448	

449 **Funding:**

This study was supported by the National Nature Science Foundations of China (Grant number 82203108), China Postdoctoral Science Foundation (Grant number 2022M722275), and the Key R&D Program of Sichuan Province, China (Grant number 2023YFS0278).

454

455 **Conflict of Interest:**

456 All authors declare no conflict of interest.

457

458 **Data Availability:**

- 459 This study was conducted using public-available data. The GWAS summary statistics
- for gut microbiota are available at <u>www.mibiogen.org</u>, and GWAS summary statistics
- 461 for irAEs are available at <u>https://zenodo.org/record/6800429</u>.

462

463464 Supplementary Information

- Table S1. All Instrumental variables used for gut microbiota in the MR analysis.
- Table S2. Full results of primary MR analysis between bacterial taxa and all-grade irAEs.
- Table S3. Full results of primary MR analysis between bacterial taxa and high-grade irAEs.
- 470 **Table S4.** Results of MR PRESS Global test.
- Table S5. Instrumental variables for irAEs in the reverse MR analysis.
- Table S6. Results of reverse MR analysis between all-grade irAEs and the identified significant gut bacterial taxa.
- Table S7. Results of reverse MR analysis between high-grade irAEs and the identified
 significant gut bacterial taxa.
- Table S8. Results of heterogeneity and horizontal pleiotropy analysis in reverse MR
 analysis.
- Table S9. PhenoScanner results of instrumental variables used for significant bacterial
- 479 taxa in the MR analysis.
- 480

481

hastorial taxta (avragura)	irAEs (outcome)	Heterogeneity test			Horizontal pleiotropy results		
bacteriai taxta (exposure)		Cochran's Q	df	p-value	Egger intercept	SE	p-value
Lachnospiraceae	High-grade irAEs	5.18	12	0.95	0.04	0.11	0.73
Verrucomicrobiaceae	High-grade irAEs	4.18	7	0.76	0.36	0.61	0.57
Eubacterium (fissicatena group)	High-grade irAEs	0.33	4	0.99	0.07	0.53	0.9
Akkermansia	High-grade irAEs	4.18	7	0.76	0.37	0.61	0.56
Anaerostipes	High-grade irAEs	4.13	6	0.66	0.38	0.2	0.11
Collinsella	High-grade irAEs	0.82	6	0.99	-0.19	0.23	0.43
Coprococcus3	High-grade irAEs	0.47	4	0.98	-0.28	0.46	0.59
Ruminiclostridium6	High-grade irAEs	3.54	7	0.83	-0.17	0.18	0.38
Lachnospiraceae	All-grade irAEs	17.3	12	0.14	0.09	0.11	0.43
Porphyromonadaceae	All-grade irAEs	0.66	4	0.96	0.05	0.28	0.87
Eubacterium (brachy group)	All-grade irAEs	1.41	5	0.92	-0.11	0.29	0.73
DefluviitaleaceaeUCG011	All-grade irAEs	0.48	4	0.98	-0.03	0.25	0.92
Peptococcus	All-grade irAEs	1.87	5	0.87	-0.12	0.24	0.66
Roseburia	All-grade irAEs	3.75	7	0.81	-0.31	0.22	0.21
RuminococcaceaeUCG004	All-grade irAEs	2.73	7	0.91	-0.23	0.3	0.47

Table 1. Results of heterogeneity and horizontal pleiotropy analysis.

df, degree of freedom; SE, standard error.

482

483

484

485 **References:**

- 1. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade.
- 487 Science. 2018 Mar 23;359(6382):1350–5.
- 488 2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al.
- ⁴⁸⁹ Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J
- 490 Med. 2010 Aug 19;363(8):711–23.
- 491 3. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al.
- 492 Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med.
 493 2015 Nov 5;373(19):1803–13.
- 494 4. Mj O, R M, Jl L, S L, Hj L, Ma M, et al. Nivolumab in patients with metastatic
- 495 DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer
- 496 (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol [Internet].
- 497 2017 Sep [cited 2023 Feb 17];18(9). Available from:
- 498 https://pubmed.ncbi.nlm.nih.gov/28734759/
- 499 5. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et

al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N

- 501 Engl J Med. 2018 May 31;378(22):2078–92.
- 6. Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat
 Commun. 2020 Jul 30;11(1):3801.
- 7. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et
 al. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. N Engl J
- 506 Med. 2015 May 21;372(21):2006–17.
- 8. Suresh K, Naidoo J. Lower Survival in Patients Who Develop Pneumonitis
- Following Immunotherapy for Lung Cancer. Clin Lung Cancer. 2020 May1;21(3):e169–70.
- 510 9. Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R,
- 511 Rutkowski P, et al. Efficacy and Safety Outcomes in Patients With Advanced
- 512 Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because
- of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. J Clin
- 514 Oncol Off J Am Soc Clin Oncol. 2017 Dec 1;35(34):3807–14.
- 515 10. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et
- al. Management of Immune-Related Adverse Events in Patients Treated With
- 517 Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology
- 518 Clinical Practice Guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2018 Jun
- 519 10;36(17):1714–68.
- 520 11. Simpson RC, Shanahan ER, Batten M, Reijers ILM, Read M, Silva IP, et al.
- 521 Diet-driven microbial ecology underpins associations between cancer immunotherapy
- outcomes and the gut microbiome. Nat Med. 2022 Nov;28(11):2344–52.
- 523 12. Jing Y, Chen X, Li K, Liu Y, Zhang Z, Chen Y, et al. Association of antibiotic
- 524 treatment with immune-related adverse events in patients with cancer receiving
- immunotherapy. J Immunother Cancer. 2022 Jan;10(1):e003779.
- 526 13. Abu-Sbeih H, Herrera LN, Tang T, Altan M, Chaftari AP, Okhuysen PC, et al.

- 527 Impact of antibiotic therapy on the development and response to treatment of immune
- checkpoint inhibitor-mediated diarrhea and colitis. J Immunother Cancer. 2019 Sep
 5;7(1):242.
- 530 14. Mohiuddin JJ, Chu B, Facciabene A, Poirier K, Wang X, Doucette A, et al.
- 531 Association of Antibiotic Exposure With Survival and Toxicity in Patients With
- 532 Melanoma Receiving Immunotherapy. J Natl Cancer Inst. 2021 Feb 1;113(2):162–70.
- 15. Yoo JY, Groer M, Dutra SVO, Sarkar A, McSkimming DI. Gut Microbiota and
- ⁵³⁴ Immune System Interactions. Microorganisms. 2020 Oct 15;8(10):1587.
- 16. Belkaid Y, Hand T. Role of the Microbiota in Immunity and inflammation. Cell.
- 536 **2014 Mar 27;157(1):121–41**.
- 17. Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al.
- 538 Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma
- patients treated with ipilimumab. Ann Oncol Off J Eur Soc Med Oncol. 2017 Jun
 1;28(6):1368–79.
- 18. McCulloch JA, Davar D, Rodrigues RR, Badger JH, Fang JR, Cole AM, et al.
- 542 Intestinal microbiota signatures of clinical response and immune-related adverse
- events in melanoma patients treated with anti-PD-1. Nat Med. 2022
- 544 Mar;28(3):545–56.
- ⁵⁴⁵ 19. Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, et al. Intestinal
- 546 microbiome analyses identify melanoma patients at risk for
- checkpoint-blockade-induced colitis. Nat Commun. 2016 Feb 2;7:10391.
- 548 20. Bajinka O, Tan Y, Abdelhalim KA, Özdemir G, Qiu X. Extrinsic factors
- influencing gut microbes, the immediate consequences and restoring eubiosis. AMB
- 550 Express. 2020 Jul 25;10(1):130.
- 21. Katan MB. Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet
- 552 Lond Engl. 1986 Mar 1;1(8479):507–8.
- 553 22. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation
- studies: a guide, glossary, and checklist for clinicians. BMJ. 2018 Jul 12;362:k601.
- ⁵⁵⁵ 23. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal
- inference in epidemiological studies. Hum Mol Genet. 2014 Sep 15;23(R1):R89–98.
- 557 24. Chen L, Peters JE, Prins B, Persyn E, Traylor M, Surendran P, et al. Systematic
- 558 Mendelian randomization using the human plasma proteome to discover potential
- therapeutic targets for stroke. Nat Commun. 2022 Oct 17;13:6143.
- 560 25. Zhang X, Theodoratou E, Li X, Farrington SM, Law PJ, Broderick P, et al.
- 561 Genetically predicted physical activity levels are associated with lower colorectal
- cancer risk: a Mendelian randomisation study. Br J Cancer. 2021 Mar;124(7):1330–8.
- 563 26. Kurilshikov A, Medina-Gomez C, Bacigalupe R, Radjabzadeh D, Wang J,
- 564 Demirkan A, et al. Large-scale association analyses identify host factors influencing
- ⁵⁶⁵ human gut microbiome composition. Nat Genet. 2021 Feb;53(2):156–65.
- 566 27. Groha S, Alaiwi SA, Xu W, Naranbhai V, Nassar AH, Bakouny Z, et al.
- ⁵⁶⁷ Germline variants associated with toxicity to immune checkpoint blockade. Nat Med.
- 568 **2022 Dec;28(12):2584–91**.
- 28. Liu X, Tong X, Zou Y, Lin X, Zhao H, Tian L, et al. Mendelian randomization
- analyses support causal relationships between blood metabolites and the gut

- 571 microbiome. Nat Genet. 2022 Jan;54(1):52–61.
- 572 29. Sanna S, van Zuydam NR, Mahajan A, Kurilshikov A, Vich Vila A, Võsa U, et al.
- 573 Causal relationships among the gut microbiome, short-chain fatty acids and metabolic
- 574 diseases. Nat Genet. 2019 Apr;51(4):600–5.
- 575 30. Zheng J, Baird D, Borges MC, Bowden J, Hemani G, Haycock P, et al. Recent
- 576 Developments in Mendelian Randomization Studies. Curr Epidemiol Rep.
- 577 2017;4(4):330-45.
- 578 31. Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al.
- 579 Guidelines for performing Mendelian randomization investigations. Wellcome Open 580 Res. 2019;4:186.
- 581 32. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal
- pleiotropy in causal relationships inferred from Mendelian randomization between
 complex traits and diseases. Nat Genet. 2018 May;50(5):693–8.
- 33. Burgess S, Dudbridge F, Thompson SG. Combining information on multiple
- instrumental variables in Mendelian randomization: comparison of allele score and
- summarized data methods. Stat Med. 2016 May 20;35(11):1880–906.
- 58734. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in
- Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
 Estimator. Genet Epidemiol. 2016 May;40(4):304–14.
- 590 35. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data
- 591 Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol.
- 592 **2017 Dec 1;46(6):1985–98.**
- 593 36. Xue H, Shen X, Pan W. Constrained maximum likelihood-based Mendelian
- randomization robust to both correlated and uncorrelated pleiotropic effects. Am J
- 595 Hum Genet. 2021 Jul 1;108(7):1251–69.
- 596 37. Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al.
- 597 Management of immune checkpoint blockade dysimmune toxicities: a collaborative
- position paper. Ann Oncol Off J Eur Soc Med Oncol. 2016 Apr;27(4):559–74.
- 599 38. Plaçais L, Dalle S, Dereure O, Trabelsi S, Dalac S, Legoupil D, et al. Risk of
- 600 irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors
- for stage III or IV melanoma: results from a matched case-control study. Ann Rheum
- 602 Dis. 2022 Oct 1;81(10):1445–52.
- 39. Liu T, Xiong Q, Li L, Hu Y. Intestinal microbiota predicts lung cancer patients at
 risk of immune-related diarrhea. Immunotherapy. 2019 Apr;11(5):385–96.
- 40. Chau J, Yadav M, Liu B, Furqan M, Dai Q, Shahi S, et al. Prospective correlation
- ⁶⁰⁶ between the patient microbiome with response to and development of
- 607 immune-mediated adverse effects to immunotherapy in lung cancer. BMC Cancer.
- 608 **2021 Jul 13;21(1):808**.
- 41. Liu W, Ma F, Sun B, Liu Y, Tang H, Luo J, et al. Intestinal Microbiome
- 610 Associated With Immune-Related Adverse Events for Patients Treated With
- Anti-PD-1 Inhibitors, a Real-World Study. Front Immunol. 2021 Dec 16;12:756872.
- 42. Zhang Y, Cheng S, Zou H, Han Z, Xie T, Zhang B, et al. Correlation of the gut
- 613 microbiome and immune-related adverse events in gastrointestinal cancer patients
- treated with immune checkpoint inhibitors. Front Cell Infect Microbiol [Internet].

- 615 2023 [cited 2023 Jun 18];13. Available from:
- 616 https://www.frontiersin.org/articles/10.3389/fcimb.2023.1099063
- 43. Dou X, Gao N, Yan D, Shan A. Sodium Butyrate Alleviates Mouse Colitis by
- 618 Regulating Gut Microbiota Dysbiosis. Anim Open Access J MDPI. 2020 Jul
- 619 **7;10(7):1154**.
- 44. Wu M, Li P, An Y, Ren J, Yan D, Cui J, et al. Phloretin ameliorates dextran
- sulfate sodium-induced ulcerative colitis in mice by regulating the gut microbiota.
- 622 Pharmacol Res. 2019 Dec;150:104489.
- 45. Johanson DM, Goertz JE, Marin IA, Costello J, Overall CC, Gaultier A.
- Experimental autoimmune encephalomyelitis is associated with changes of the
- microbiota composition in the gastrointestinal tract. Sci Rep. 2020 Sep
- 626 **16;10(1):15183**.
- 46. Ning J, Huang SY, Chen SD, Zhang YR, Huang YY, Yu JT. Investigating Casual
- Associations Among Gut Microbiota, Metabolites, and Neurodegenerative Diseases:
- A Mendelian Randomization Study. J Alzheimers Dis JAD. 2022;87(1):211–22.
- 47. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, et al. Gut
- microbiome influences efficacy of PD-1–based immunotherapy against epithelial
 tumors. Science. 2018 Jan 5;359(6371):91–7.
- 48. Lee KA, Thomas AM, Bolte LA, Björk JR, de Ruijter LK, Armanini F, et al.
- 634 Cross-cohort gut microbiome associations with immune checkpoint inhibitor response 635 in advanced melanoma. Nat Med. 2022 Mar;28(3):535–44.
- 49. Derosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S, et al. Intestinal
- 637 Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with
- advanced non-small-cell lung cancer. Nat Med. 2022 Feb;28(2):315–24.
- 50. Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL,
- 640 et al. Fecal microbiota transplantation for refractory immune checkpoint
- 641 inhibitor-associated colitis. Nat Med. 2018 Dec;24(12):1804–8.
- 642 51. Wang L, Tang L, Feng Y, Zhao S, Han M, Zhang C, et al. A purified membrane
- 643 protein from Akkermansia muciniphila or the pasteurised bacterium blunts colitis
- associated tumourigenesis by modulation of CD8+ T cells in mice. Gut. 2020
- 645 Nov;69(11):1988–97.
- 646 52. Chen J, Wright K, Davis JM, Jeraldo P, Marietta EV, Murray J, et al. An
- 647 expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis.
- 648 Genome Med. 2016 Apr 21;8(1):43.
- 53. Miyauchi E, Shimokawa C, Steimle A, Desai MS, Ohno H. The impact of the gut
- microbiome on extra-intestinal autoimmune diseases. Nat Rev Immunol. 2023
- 651 Jan;23(1):9–23.
- 52 54. Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse
- 653 effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
- 654 Nat Rev Clin Oncol. 2019 Sep;16(9):563–80.
- 55. Sostow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events
- Associated with Immune Checkpoint Blockade. N Engl J Med. 2018 Jan
- 657 **11;378(2):158–68**.
- 56. Du C, Yao SY, Ljunggren-Rose Å, Sriram S. Chlamydia pneumoniae Infection of

- 659 the Central Nervous System Worsens Experimental Allergic Encephalitis. J Exp Med.
- 660 **2002** Dec 16;196(12):1639–44.
- 661 57. Rodríguez Y, Rojas M, Pacheco Y, Acosta-Ampudia Y, Ramírez-Santana C,
- 662 Monsalve DM, et al. Guillain–Barré syndrome, transverse myelitis and infectious
- 663 diseases. Cell Mol Immunol. 2018 Jun;15(6):547–62.
- 58. Gülden E, Wong FS, Wen L. The gut microbiota and Type 1 Diabetes. Clin
- 665 Immunol. 2015 Aug 1;159(2):143–53.
- 59. Lundberg K, Kinloch A, Fisher BA, Wegner N, Wait R, Charles P, et al.
- 667 Antibodies to citrullinated α-enolase peptide 1 are specific for rheumatoid arthritis
- and cross-react with bacterial enolase. Arthritis Rheum. 2008;58(10):3009–19.
- 669 60. Tanaka A, Leung PSC, Gershwin ME. Pathogen infections and primary biliary
- 670 cholangitis. Clin Exp Immunol. 2019 Jan 1;195(1):25–34.
- 671 61. Rojas M, Restrepo-Jiménez P, Monsalve DM, Pacheco Y, Acosta-Ampudia Y,
- Ramírez-Santana C, et al. Molecular mimicry and autoimmunity. J Autoimmun. 2018
- 673 Dec;95:100–23.
- 674 62. Wang SJ, Dougan SK, Dougan M. Immune mechanisms of toxicity from
- checkpoint inhibitors. Trends Cancer. 2023 Jul 1;9(7):543–53.
- 676 63. Park J, Kim M, Kang SG, Jannasch AH, Cooper B, Patterson J, et al. Short-chain
- 677 fatty acids induce both effector and regulatory T cells by suppression of histone
- deacetylases and regulation of the mTOR–S6K pathway. Mucosal Immunol. 2015
- 679 Jan;8(1):80–93.
- 680 64. Luu M, Riester Z, Baldrich A, Reichardt N, Yuille S, Busetti A, et al. Microbial
- short-chain fatty acids modulate CD8+ T cell responses and improve adoptive
- immunotherapy for cancer. Nat Commun. 2021 Jul 1;12(1):4077.
- 683 65. Zhou G, Zhang N, Meng K, Pan F. Interaction between gut microbiota and
- 684 immune checkpoint inhibitor-related colitis. Front Immunol. 2022 Oct
- 685 **27;13:1001623**.
- 686 66. BÖCKER U, NEBE T, HERWECK F, HOLT L, PANJA A, JOBIN C, et al.
- Butyrate modulates intestinal epithelial cell-mediated neutrophil migration. Clin Exp
 Immunol. 2003 Jan;131(1):53–60.
- 689 67. Lee C, Kim BG, Kim JH, Chun J, Im JP, Kim JS. Sodium butyrate inhibits the
- 690 NF-kappa B signaling pathway and histone deacetylation, and attenuates experimental
- colitis in an IL-10 independent manner. Int Immunopharmacol. 2017 Oct;51:47–56.
- 692 68. den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM.
- ⁶⁹³ The role of short-chain fatty acids in the interplay between diet, gut microbiota, and
- host energy metabolism. J Lipid Res. 2013 Sep;54(9):2325–40.
- 695 69. Wang Y, Jenq RR, Wargo JA, Watowich SS. Microbiome influencers of
- checkpoint blockade-associated toxicity. J Exp Med. 2023 Mar 6;220(3):e20220948.
- 697 70. Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al.
- 698 Management of Immune-Related Adverse Events in Patients Treated With Immune
- 699 Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021 Dec
- 700 20;39(36):4073–126.
- 701 71. Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison
- 702 RM, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in

- 703 melanoma patients. Science. 2021 Feb 5;371(6529):595–602.
- 704 72. Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, et al.
- Fecal microbiota transplant promotes response in immunotherapy-refractory
- 706 melanoma patients. Science. 2021 Feb 5;371(6529):602–9.
- 707 73. Chen M, Liu M, Li C, Peng S, Li Y, Xu X, et al. Fecal Microbiota
- 708 Transplantation Effectively Cures a Patient With Severe Bleeding Immune
- 709 Checkpoint Inhibitor-Associated Colitis and a Short Review. Front Oncol. 2022 Jun
- 710 10;12:913217.
- 711 74. Soularue E, Lepage P, Colombel JF, Coutzac C, Faleck D, Marthey L, et al.
- Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut. 2018
- 713 Nov 1;67(11):2056–67.
- 714

715 **Figure legends:**

- 716 **Figure 1.** Overview of the study design.
- 717 Initially, IVs were selected from the summary GWAS data pertaining to the gut
- microbiota and irAEs. Subsequently, by employing thresholds of p-value (IVW) <
- 0.05 and p-value (MR PRESSO) < 0.05, the identified gut microbiota that exhibited
- statistically significant associations were taken into further analysis (Created withBioRender.com).
- Figure 2. Forest plots of MR results for the causal association between the identified
- eight gut microbial taxa and high-grade irAEs. NSNP = number of SNPs; Beta =
- effect size from the exposure to the outcome; CI = confidence interval.
- **Figure 3.** Forest plots of MR results for the causal association between the identified seven gut microbial taxa and all-grade irAEs. NSNP = number of SNPs; Beta = effect size from the exposure to the outcome; CI = confidence interval.
- Figure 4. Scatter plots of MR analysis between the gut microbial taxa and high-grade
- 729 irAEs.
- Figure 5. Scatter plots of MR analysis between the gut microbial taxa and all-grade
- 731 irAEs.
- Figure 6. Leave-one-out plots of MR analysis between the gut microbial taxa and
- 733 high-grade irAEs.
- Figure 7. Leave-one-out plots of MR analysis between the gut microbial taxa and
- 735 all-grade irAEs.
- 736
- 737 Figure S1. Illustration of MR assumptions
- 738



High-grage irAEs



Genus level







All-grade irAEs



Porphyromonadaceae



Genus level









High-grade irAEs

Family level

Lachnospiraceae







Verrucomicrobiaceae

Genus level

Ruminiclostridium6

Coprococcus3

Anaerostipes



medRxiv preprint doi: https://doi.org/10.1101/2023.07.24.23292742; this version posted July 27, 2023. The (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to dis	he copyright holder for this preprint display the preprint in perpetuity.	
It is made available under a CC-BY-NC 4.0 International license .	Akkermansia	3
	AKKermansia	1

Collinsella

Eubacterium (fissicatena group)











All-grade irAEs

Family level

Lachnospiraceae



Porphyromonadaceae



Genus level



RuminococcaceaeUCG004

0.10

0.4 SNP effect on irAEs 0.2 -0.0--0.2 -0.075 0.100 0.125 0.150 0.050 SNP effect on genus.RuminococcaceaeUCG004 **Defluviitaleaceae**UCG011



01/2023.07.24.23292742; this version posted July 27, 2023. The copyright holder for this preprin **bt certified by peer review**) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Eubacterium (brachy group)

Peptococcus



High-grade irAEs

Family level

Lachnospiraceae



Verrucomicrobiaceae

2.5



Genus level



All-grade irAEs

Family level

rs2910921 rs79086868 rs1205443 rs11841382 rs9929145 rs7359994 rs11139361 rs112040820 rs959845 rs11979110



Genus level









Peptococcus

